APPROACHES
Co-Design
At the start of the Plus Project, the country specific models of PMC were not yet designed, but instead were developed through a country-led co-design process completed in late 2021 for Benin, Cameroon and Cote d’Ivoire and for Mozambique in 2022. Through a four-day national-level co-design workshop, the project brought together key stakeholders to co-design the PMC model to be implemented in each country under the Plus Project.
Please see the Countries section to explore the different models co-designed for each country.
THE CO-DESIGN PROCESS CONSISTED OF VARIOUS STEPS INCLUDING:
• Stakeholder Mapping to better understand the stakeholders and their different roles.
• Preparation by the NMCP, EPI, and CSO representatives to review and prepare relevant data to present at the workshops (including the National Malaria Strategy, EPI coverage data, etc.)
• Working with SwissTPH on modelling the impact of different PMC scenarios to orient the project team and to share with participants during the workshop
• Holding a 2-day facilitation team pre-meeting, including with NMCP partners, prior to the workshop to review all sessions, adapt to the country context, and practice the participatory activities to be conducted during the workshop.
02
Evidence Generation
The evaluations under the Plus Project fall under five categories and will answer the questions below.
- How receptive to PMC are policymakers in the three focus countries?
- What evidence and other factors would promote and facilitate national adoption of an PMC policy?
- What proportion of children under 2 years of age receive the target number of doses of PMC?
- What is the effectiveness of different delivery models of PMC (including equity of access, acceptability, feasibility)?
- What is the impact on the systems through which PMC is delivered and on the interventions with which it is co-delivered?
- What is the protective effect of PMC against clinical malaria, severe malaria and anaemia?
- What is the incidence of malaria in children under 2 years of age in PMC implementation areas compared to control areas?
- What are the costs of delivering PMC at scale?
- Would adopting PMC be a cost-effective (and equitable) use of resources in the focus countries?
- How does the cost-effectiveness of PMC compare to other interventions targeting children under 2 years of age in the focus countries?
- What is the SP resistance profile of parasite populations in the intervention sites in the focus countries?
- What is the impact of different combinations and frequencies of parasite SP-associated resistant mutations on SP’s ability to clear infections and prevent new infection?
- What countries (or administrative areas within countries) have a parasite profile that is compatible with PMC with SP protection?